STOCK TITAN

Alector to Present at Stifel’s 3rd Annual CNS Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that its president, Shehnaaz Suliman, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on April 1, 2021, at 9:30 a.m. ET. The event will be accessible via a live webcast on the Alector website, with a replay available for 30 days afterward. Alector is pioneering treatments for neurodegenerative diseases by targeting immune dysfunction, particularly in Alzheimer's and frontotemporal dementia patient populations.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on Thursday, April 1, 2021, at 9:30 a.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts

Media:
Erica Jefferson
Vice President, Communications and Public Affairs
Alector, Inc.
301-928-4650
erica.jefferson@alector.com

1AB
Dan Budwick
973-271-6085
dan@1abmedia.com

or

Investors:
Alector, Inc.
ir@alector.com


FAQ

When will Alector's fireside chat take place?

Alector's fireside chat will occur on April 1, 2021, at 9:30 a.m. ET.

Who will represent Alector at the Stifel CNS Day?

Shehnaaz Suliman, M.D., MBA, M.Phil., will represent Alector.

Where can I watch the Alector fireside chat?

The fireside chat will be streamed live on the Alector website under the 'Events & Presentations' section.

What is Alector's focus in biotechnology?

Alector focuses on immuno-neurology to develop treatments for neurodegenerative diseases.

How can I access the replay of Alector's fireside chat?

A replay will be available on Alector's website for 30 days after the event.

Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

386.83M
88.12M
10.02%
86.07%
4.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO